Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Income Before Tax

Profit after all operating and non-operating items but before income tax.

Wave Life Sciences Ltd.NASDAQ: WVE

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$26.09M, compared with -$46.88M a year earlier. Trailing-twelve-month income before tax was -$183.59M.

Context

  • Income before tax amounted to 478.3% of revenue in FY2025, up 388.8 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$26.09M or moves back toward the trailing-twelve-month quarterly average of -$45.9M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.09M+50.9% QoQ
Last fiscal yearDec 2025
-$204.38M-110.7% YoY
LTMMar 2026
-$183.59M-63.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.4%——
1 year-110.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(204.38M) USD
Year-over-year change
-110.7%

Income Before Tax vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -63.4% is the 7th highest of 10, against a peer median of -44.5%.
  • Income before tax amounts to 255.7% of revenue for WVE, versus a peer median of 173.5%.
WVE Competitors
Income Before Tax for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$799.57M USD+310.6%—16.6%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$24.47M USD+114.9%—1.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.61M EUR-50.1%—339.3%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$48.88M USD-44.5%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-14.7%—173.5%
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$171.05M USD-431.8%—533.2%
WVEWave Life Sciences Ltd.LTM Mar 2026-$183.59M USD-63.4%—255.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$394.6M USD+25.0%—597.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$543.8M USD-110.2%—56.7%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$723.91M USD-1504.8%—160.6%
Peer median (excluding WVE) —-44.5%—173.5%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.